A Novel Insulin Combination of Insulin Degludec and Insulin Aspart Achieves a More Stable Overnight Glucose Profile than Insulin Glargine: Results from Continuous Glucose Monitoring in a Proof-of-Concept Trial

PURPOSE: Insulin degludec coformulated with insulin aspart (as IDegAsp) can cover 24 h basal insulin and postprandial insulin requirements after a main meal with one injection. We compared glycemic stability following IDegAsp or insulin glargine (IGlar) given before the evening meal in patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Liebl, Andreas, Davidson, Jaime, Mersebach, Henriette, Dykiel, Patrik, Tack, Cees J., Heise, Tim
Format: Artigo
Sprache:Inglês
Veröffentlicht: Diabetes Technology Society 2013
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3876378/
https://ncbi.nlm.nih.gov/pubmed/24124961
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge